Acalabrutinib for treating chronic lymphocytic leukaemia

As of April 2021, MARA’s assessment finds Acalabrutinib’s reimbursement risk concentrated in comparator selection, with cost effectiveness a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs clinical effectiveness: how much additional benefit the drug demonstrated over the care patients already receive — the first question every payer asks. The strength recorded in cost effectiveness carries weight because that domain asks whether the price asked stands in a defensible relationship to the benefit delivered — the core of most European reimbursement decisions.

Oncology

This rating sits within MARA’s Oncology coverage, alongside 153 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

Acalabrutinib shows moderate benefit over current care, particularly in increasing progression-free survival compared to chlorambucil plus obinutuzumab. However, the overall survival benefit remains uncertain due to immature data, which limits the strength of the evidence.

Does the economic case hold at the expected price? — Cost effectiveness

The cost-effectiveness analysis indicates that acalabrutinib is likely to be cost-saving compared to ibrutinib for high-risk patients and remains within acceptable thresholds for untreated CLL when FCR or BR is unsuitable.

Is there quality-of-life evidence payers weigh? — Quality of life

The evidence indicates that acalabrutinib is generally well tolerated and associated with fewer adverse effects compared to current treatments, suggesting a moderate improvement in quality of life for patients with CLL.

Does the safety profile hold up for payers? — Safety and Adverse Effects

Acalabrutinib has a very good tolerability profile with fewer adverse effects compared to existing treatments, indicating a strong safety profile.

Was the drug compared against what payers expect? — Comparator Selection

The company did not present direct comparisons with all relevant comparators, particularly venetoclax plus rituximab, which limits the robustness of the evidence.

Is the population defined the way payers need it? — Patient Population and Subgroups

The trial populations are broadly representative of the intended patient population, although there are some gaps in subgroup analyses for those suitable for FCR or BR.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

Acalabrutinib can be integrated into existing treatment pathways with minor adjustments, as it offers a new option for patients who cannot tolerate current therapies.

Are the wider system costs understood? — Resource Use and Cost Implications

The budget impact is manageable, and the treatment is likely to be resource-efficient, particularly given the cost-saving potential compared to ibrutinib.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

The evidence is based on well-conducted RCTs, although there are some uncertainties regarding the indirect comparisons and the maturity of survival data.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

There are notable uncertainties regarding overall survival estimates and the distribution of subsequent treatments, which could impact the decision-making process.

Request the current rating

Be alerted when this rating changes:

Related Reimbursement Risk Assessments

Public record

The entries below are official decisions and assessments concerning this drug and indication, listed with their dates as a matter of record. The assessment on this page reflects the evidence available as of its date.

19 August 2026 — United Kingdom (NICE), technology appraisal TA1185: recommended in combination with venetoclax, with or without obinutuzumab, for untreated chronic lymphocytic leukaemia (commercial arrangements apply). official record

Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.